Free Trial

Dr. Hönle (ETR:HNL) Shares Down 3.3% - Here's Why

Dr. Hönle logo with Industrials background
Image from MarketBeat Media, LLC.

Key Points

  • Dr. Hönle shares were down 3.3% to €8.88 on Thursday, with roughly 3,017 shares traded and a prior close of €9.18.
  • The company is small (market cap ~$52.9M) and shows negative earnings (P/E -3.99, PEG -0.39), with notable leverage and modest liquidity (debt-to-equity 62.78, quick ratio 0.85, current ratio 1.80).
  • Dr. Hönle supplies industrial UV technologies via three segments—Adhesives, Equipment & Systems, and Glass & Lamps—for uses including electronics, automotive, medical tech, curing/drying processes and surface disinfection.
  • MarketBeat previews top five stocks to own in May.

Dr. Hönle AG (ETR:HNL - Get Free Report) shares were down 3.3% during trading on Thursday . The company traded as low as €8.88 and last traded at €8.88. Approximately 3,017 shares changed hands during mid-day trading, The stock had previously closed at €9.18.

Dr. Hönle Trading Down 3.3%

The business has a fifty day simple moving average of €8.64 and a 200-day simple moving average of €8.07. The company has a debt-to-equity ratio of 62.78, a quick ratio of 0.85 and a current ratio of 1.80. The firm has a market cap of $52.92 million, a price-to-earnings ratio of -3.99, a PEG ratio of -0.39 and a beta of 1.45.

About Dr. Hönle

(Get Free Report)

Dr. Hönle AG engages in the supply of industrial UV technologies and systems in Germany and internationally. The company operates through three segments: Adhesives, Equipment & Systems, and Glass & Lamps. The Adhesives segment provides industrial adhesives for applications, such as consumer electronics, automotive, optics and opto-electronics, medical technology, and glass processing. The Equipment & Systems segment engages in the provision of solutions used for drying inks and coatings, curing adhesives and plastics, disinfecting surfaces, and solar simulation.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Dr. Hönle Right Now?

Before you consider Dr. Hönle, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Hönle wasn't on the list.

While Dr. Hönle currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines